Are we ready to recommend aspirin for cancer prevention?

doi:10.1016/S0140-6736(11)61654-1

Comment

. 2012 Apr 28;379(9826):1569-71.

doi: 10.1016/S0140-6736(11)61654-1. Epub 2012 Mar 21.

Are we ready to recommend aspirin for cancer prevention?

Andrew T Chan¹, Nancy R Cook

Affiliations

PMID: 22440945
PMCID: PMC3415297
DOI: 10.1016/S0140-6736(11)61654-1

Comment

Are we ready to recommend aspirin for cancer prevention?

Andrew T Chan et al. Lancet. 2012.

. 2012 Apr 28;379(9826):1569-71.

doi: 10.1016/S0140-6736(11)61654-1. Epub 2012 Mar 21.

Authors

Andrew T Chan¹, Nancy R Cook

Affiliation

¹ Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.

PMID: 22440945
PMCID: PMC3415297
DOI: 10.1016/S0140-6736(11)61654-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: ATC has served as a consultant to Bayer HealthCare and Millennium Pharmaceuticals. NRC declares she has no conflicts of interest.

Comment on

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.
Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW. Rothwell PM, et al. Lancet. 2012 Apr 28;379(9826):1602-12. doi: 10.1016/S0140-6736(11)61720-0. Epub 2012 Mar 21. Lancet. 2012. PMID: 22440946 Review.

Cited by

Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial.
Yaqub S, Bjørnbeth BA, Angelsen JH, Fristrup CW, Grønbech JE, Hemmingsson O, Isaksson B, Juel IS, Larsen PN, Lindell G, Mortensen FV, Mortensen KE, Rizell M, Sandström P, Sandvik OM, Sparrelid E, Taflin H, Taskén K; ASAC study group. Yaqub S, et al. Trials. 2021 Sep 20;22(1):642. doi: 10.1186/s13063-021-05587-w. Trials. 2021. PMID: 34544470 Free PMC article.
Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.
Masoudkabir F, Sarrafzadegan N, Gotay C, Ignaszewski A, Krahn AD, Davis MK, Franco C, Mani A. Masoudkabir F, et al. Atherosclerosis. 2017 Aug;263:343-351. doi: 10.1016/j.atherosclerosis.2017.06.001. Epub 2017 Jun 2. Atherosclerosis. 2017. PMID: 28624099 Free PMC article. Review.
Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.
Volpe M, Battistoni A, Gallo G, Coluccia R, De Caterina R. Volpe M, et al. High Blood Press Cardiovasc Prev. 2017 Sep;24(3):331-339. doi: 10.1007/s40292-017-0213-4. Epub 2017 Jun 1. High Blood Press Cardiovasc Prev. 2017. PMID: 28573479 Review.
Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence.
Cronin-Fenton DP, Heide-Jørgensen U, Ahern TP, Lash TL, Christiansen P, Ejlertsen B, Sørensen HT. Cronin-Fenton DP, et al. Epidemiology. 2016 Jul;27(4):586-93. doi: 10.1097/EDE.0000000000000480. Epidemiology. 2016. PMID: 27007644 Free PMC article.
Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice.
Battistoni A, Mastromarino V, Volpe M. Battistoni A, et al. Clin Cardiol. 2015 Jun;38(6):387-94. doi: 10.1002/clc.22394. Epub 2015 Apr 14. Clin Cardiol. 2015. PMID: 25873555 Free PMC article. Review.

See all "Cited by" articles

References

1. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognon G, et al. Short-term effects of daily aspirin on cancer incidence, mortality and non-vascular death: analysis of the time-course of risks and benefits in randomised controlled trials. Lancet. 2011 - PubMed
1. Aspirin for the prevention of cardiovascular disease: U S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009 Mar 17;150(6):396–404. - PubMed
1. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007 Mar 6;146(5):361–4. - PubMed
1. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009 Feb 18;101(4):256–66. - PMC - PubMed
1. Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 2011 May;4(5):655–65. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognon G, et al. Short-term effects of daily aspirin on cancer incidence, mortality and non-vascular death: analysis of the time-course of risks and benefits in randomised controlled trials. Lancet. 2011 - PubMed

[2] Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognon G, et al. Short-term effects of daily aspirin on cancer incidence, mortality and non-vascular death: analysis of the time-course of risks and benefits in randomised controlled trials. Lancet. 2011 - PubMed

[3] Aspirin for the prevention of cardiovascular disease: U S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009 Mar 17;150(6):396–404. - PubMed

[4] Aspirin for the prevention of cardiovascular disease: U S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009 Mar 17;150(6):396–404. - PubMed

[5] Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007 Mar 6;146(5):361–4. - PubMed

[6] Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007 Mar 6;146(5):361–4. - PubMed

[7] Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009 Feb 18;101(4):256–66. - PMC - PubMed

[8] Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009 Feb 18;101(4):256–66. - PMC - PubMed

[9] Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 2011 May;4(5):655–65. - PMC - PubMed

[10] Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 2011 May;4(5):655–65. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Are we ready to recommend aspirin for cancer prevention?

Affiliation

Are we ready to recommend aspirin for cancer prevention?

Authors

Affiliation

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical